| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
SH2 domains of Src family kinases. EPQpYEEIPIYL is a phosphopeptide ligand for the SH2 domain. It contains a phosphorylated tyrosine residue (pY) that binds to the SH2 domain with high affinity. This binding disrupts the autoinhibitory intramolecular interaction between the SH2 domain and the kinase domain, leading to activation of the kinase.
|
|---|---|
| ln Vitro |
The hmT-derived phosphopeptide pY324, with the sequence EPQpYEEIPIYL, demonstrates the highest affinity binding to GST fusion proteins of the Lck SH2 domain and the Src SH2 domain [1].
EPQpYEEIPIYL is a phosphopeptide that binds to the SH2 domain with high affinity. It activates Src family members, including Lck, Hck, and Fyn, by binding to their SH2 domains. The compound activates Src family kinases, which are involved in a wide range of cellular processes including proliferation, differentiation, adhesion, and migration. Activation is achieved through a mechanism that mimics the binding of phosphorylated tyrosines on activated receptors or adaptor proteins. |
| ln Vivo |
No specific in vivo activity data are reported. EPQpYEEIPIYL is a research tool used in in vitro and cell-free assays to study SH2 domain function and Src family kinase activation. It is not typically used in vivo due to its phosphopeptide nature, which makes it susceptible to phosphatase degradation and poor cellular permeability. It may be delivered by microinjection or using cell-penetrating peptide strategies for cellular studies.
|
| Enzyme Assay |
Cell-free SH2 domain binding assays are performed using purified SH2 domains (e.g., from Lck, Hck, Fyn, or Src). The SH2 domain is immobilized on a sensor chip or assay plate. Increasing concentrations of EPQpYEEIPIYL (0.01-10,000 nM) are added in binding buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Tween-20). Binding affinity is measured by surface plasmon resonance (SPR) or ELISA. For activation studies, full-length Src family kinases are used. The kinase is incubated with EPQpYEEIPIYL (0.1-1000 nM) in assay buffer. Kinase activity is measured by phosphorylation of a peptide substrate using luminescence (ADP-Glo) or 33P incorporation. EC50 for activation is determined.
|
| Cell Assay |
Cells (e.g., T cells, macrophages) are treated with EPQpYEEIPIYL for 5-30 minutes. However, due to poor cell permeability of phosphopeptides, delivery methods such as microinjection, electroporation, or conjugation to cell-penetrating peptides (e.g., TAT) are required. Alternatively, the compound can be used in cell lysates. Activation of Src family kinases is assessed by measuring phosphorylation of Src family kinase activation loop sites (e.g., pY416 for Src) by Western blot using phospho-specific antibodies. Downstream signaling (e.g., pERK, pAKT) is also assessed. No specific cellular protocols are available.
|
| Animal Protocol |
No in vivo animal protocols are reported for EPQpYEEIPIYL. As a phosphopeptide with poor stability and permeability, it is not suitable for routine in vivo administration without extensive formulation (e.g., encapsulation, conjugation, or use of phosphatase inhibitors). It is primarily used as an in vitro and cell-free research tool. For in vivo applications, more stable non-phosphorylated or peptidomimetic analogs would be required.
|
| ADME/Pharmacokinetics |
No specific PK data are reported for EPQpYEEIPIYL. The molecular weight is 1473.52 (C66H97N12O24P). CAS 147612-86-0. The compound is a phosphopeptide and is not orally bioavailable. It is soluble in water (2 mg/mL) and DMSO. Storage: powder at -20degC (3 years), in water at -80degC (6 months). The half-life in plasma or tissues is expected to be very short (minutes) due to rapid dephosphorylation by phosphatases and degradation by proteases. Cell permeability is poor.
|
| Toxicity/Toxicokinetics |
No toxicity data are reported for EPQpYEEIPIYL. As a research-grade phosphopeptide, standard toxicological assessments have not been performed. The compound is not intended for in vivo use. At concentrations used in cell-free assays (nM-uM), no toxicity concerns exist. For research use only. Not for human use.
|
| References | |
| Additional Infomation |
Other information: EPQpYEEIPIYL (CAS 147612-86-0) is a research-grade phosphopeptide, not FDA-approved. It is a ligand for the Src homology 2 (SH2) domain and activates Src family members including Lck, Hck, and Fyn. The sequence contains a phosphorylated tyrosine residue (pY). It is a valuable tool for studying SH2 domain function and Src family kinase activation mechanisms. Purity ≥98%. For research use only.
|
| Molecular Formula |
C66H97N12O24P
|
|---|---|
| Molecular Weight |
1473.5161588192
|
| Exact Mass |
1472.647
|
| CAS # |
147612-86-0
|
| PubChem CID |
44300143
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.586
|
| LogP |
-2.5
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
43
|
| Heavy Atom Count |
103
|
| Complexity |
3030
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
P(=O)(O)(O)OC1C=CC(=CC=1)C[C@@H](C(N[C@@H](CCC(=O)O)C(N[C@@H](CCC(=O)O)C(N[C@@H]([C@@H](C)CC)C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CC(C)C)=O)CC1C=CC(=CC=1)O)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@@H]1CCCN1C([C@H](CCC(=O)O)N)=O)=O)=O
|
| InChi Key |
DLNQPUNIZRZGQD-VBIHGRSYSA-N
|
| InChi Code |
InChI=1S/C66H97N12O24P/c1-7-35(5)54(63(94)73-46(32-37-13-17-39(79)18-14-37)60(91)74-47(66(97)98)31-34(3)4)75-62(93)49-12-10-30-78(49)65(96)55(36(6)8-2)76-58(89)44(24-28-53(85)86)69-56(87)43(23-27-52(83)84)70-59(90)45(33-38-15-19-40(20-16-38)102-103(99,100)101)72-57(88)42(22-25-50(68)80)71-61(92)48-11-9-29-77(48)64(95)41(67)21-26-51(81)82/h13-20,34-36,41-49,54-55,79H,7-12,21-33,67H2,1-6H3,(H2,68,80)(H,69,87)(H,70,90)(H,71,92)(H,72,88)(H,73,94)(H,74,91)(H,75,93)(H,76,89)(H,81,82)(H,83,84)(H,85,86)(H,97,98)(H2,99,100,101)/t35-,36-,41-,42-,43-,44-,45-,46-,47-,48-,49-,54-,55-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-amino-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 2 mg/mL (1.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6786 mL | 3.3932 mL | 6.7865 mL | |
| 5 mM | 0.1357 mL | 0.6786 mL | 1.3573 mL | |
| 10 mM | 0.0679 mL | 0.3393 mL | 0.6786 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
